CD8A and neoplasm: Immune checkpoint inhibitors, such as anti-PD1 or anti-CTLA4 antibodies, usually block the inhibitory signalings in T cells, or deplete immunosuppressive cells, such as regulatory T cells, and therefore activate T effectors, such as CD8+ T cell, to inhibit tumor progression [11, 17, 28, 29].